AstraZeneca PLC Logo

AstraZeneca PLC

AZNCF

(2.8)
Stock Price

127,48 USD

14.68% ROA

16.57% ROE

37.48x PER

Market Cap.

241.411.158.800,00 USD

82.47% DER

1.9% Yield

12.68% NPM

AstraZeneca PLC Stock Analysis

AstraZeneca PLC Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AstraZeneca PLC Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (16.96%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

5 DER

The stock has a reasonable amount of debt compared to its ownership (80%), suggesting a balanced financial position and a moderate level of risk.

6 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

7 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (7.187) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

8 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.31x) suggests it's overvalued, potentially making it an expensive investment.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

AstraZeneca PLC Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AstraZeneca PLC Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

AstraZeneca PLC Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AstraZeneca PLC Revenue
Year Revenue Growth
1990 7.349.253.501
1991 7.351.895.512 0.04%
1992 6.034.914.231 -21.82%
1993 6.567.658.718 8.11%
1994 7.004.049.215 6.23%
1995 7.568.452.932 7.46%
1996 9.184.162.756 17.59%
1997 8.586.259.340 -6.96%
1998 9.145.987.218 6.12%
1999 18.435.929.209 50.39%
2000 18.115.963.675 -1.77%
2001 23.570.530.781 23.14%
2002 17.849.807.521 -32.05%
2003 18.849.000.000 5.3%
2004 21.426.000.000 12.03%
2005 23.950.000.000 10.54%
2006 26.475.000.000 9.54%
2007 29.559.000.000 10.43%
2008 31.601.000.000 6.46%
2009 32.804.000.000 3.67%
2010 33.269.000.000 1.4%
2011 33.591.000.000 0.96%
2012 27.973.000.000 -20.08%
2013 25.711.000.000 -8.8%
2014 26.095.000.000 1.47%
2015 24.708.000.000 -5.61%
2016 23.002.000.000 -7.42%
2017 22.465.000.000 -2.39%
2018 22.090.000.000 -1.7%
2019 24.384.000.000 9.41%
2020 26.617.000.000 8.39%
2021 37.417.000.000 28.86%
2022 44.351.000.000 15.63%
2023 45.968.000.000 3.52%
2023 46.914.698.989 2.02%
2024 51.857.185.180 9.53%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AstraZeneca PLC Research and Development Expenses
Year Research and Development Expenses Growth
1990 704.062.343
1991 703.566.483 -0.07%
1992 676.444.269 -4.01%
1993 767.706.052 11.89%
1994 809.843.190 5.2%
1995 848.321.898 4.54%
1996 1.030.927.835 17.71%
1997 1.079.481.584 4.5%
1998 1.175.201.261 8.14%
1999 2.921.562.378 59.77%
2000 2.894.611.064 -0.93%
2001 3.965.407.378 27%
2002 3.070.514.617 -29.14%
2003 3.451.000.000 11.03%
2004 3.467.000.000 0.46%
2005 3.379.000.000 -2.6%
2006 3.902.000.000 13.4%
2007 5.089.000.000 23.32%
2008 4.953.000.000 -2.75%
2009 4.409.000.000 -12.34%
2010 5.318.000.000 17.09%
2011 5.523.000.000 3.71%
2012 5.243.000.000 -5.34%
2013 4.821.000.000 -8.75%
2014 5.579.000.000 13.59%
2015 5.997.000.000 6.97%
2016 5.890.000.000 -1.82%
2017 5.757.000.000 -2.31%
2018 5.932.000.000 2.95%
2019 5.958.000.000 0.44%
2020 5.991.000.000 0.55%
2021 9.736.000.000 38.47%
2022 9.762.000.000 0.27%
2023 10.336.000.000 5.55%
2023 10.594.236.341 2.44%
2024 11.527.381.708 8.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AstraZeneca PLC General and Administrative Expenses
Year General and Administrative Expenses Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 6.000.961.584 100%
2003 6.856.000.000 12.47%
2004 8.268.000.000 17.08%
2005 8.906.000.000 7.16%
2006 9.322.000.000 4.46%
2007 10.612.000.000 12.16%
2008 11.204.000.000 5.28%
2009 11.332.000.000 1.13%
2010 10.445.000.000 -8.49%
2011 11.161.000.000 6.42%
2012 9.839.000.000 -13.44%
2013 12.206.000.000 19.39%
2014 13.000.000.000 6.11%
2015 11.112.000.000 -16.99%
2016 9.413.000.000 -18.05%
2017 10.233.000.000 8.01%
2018 0 0%
2019 11.682.000.000 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -3.760.790.587 100%
2024 19.716.000.000 119.07%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AstraZeneca PLC EBITDA
Year EBITDA Growth
1990 1.521.932.024
1991 1.670.970.397 8.92%
1992 1.202.736.110 -38.93%
1993 1.371.220.637 12.29%
1994 1.640.010.631 16.39%
1995 1.752.271.463 6.41%
1996 2.233.106.141 21.53%
1997 2.266.415.393 1.47%
1998 2.400.199.186 5.57%
1999 5.261.880.419 54.39%
2000 5.719.022.583 7.99%
2001 7.486.987.780 23.61%
2002 5.349.640.009 -39.95%
2003 5.492.000.000 2.59%
2004 6.347.000.000 13.47%
2005 8.494.000.000 25.28%
2006 10.449.000.000 18.71%
2007 11.875.000.000 12.01%
2008 13.025.000.000 8.83%
2009 14.092.000.000 7.57%
2010 14.751.000.000 4.47%
2011 14.414.000.000 -2.34%
2012 11.194.000.000 -28.77%
2013 8.345.000.000 -34.14%
2014 5.491.000.000 -51.98%
2015 6.996.000.000 21.51%
2016 7.293.000.000 4.07%
2017 6.771.000.000 -7.71%
2018 7.165.000.000 5.5%
2019 7.016.000.000 -2.12%
2020 8.371.000.000 16.19%
2021 7.565.000.000 -10.65%
2022 9.327.000.000 18.89%
2023 13.304.000.000 29.89%
2023 14.690.606.112 9.44%
2024 16.509.487.216 11.02%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AstraZeneca PLC Gross Profit
Year Gross Profit Growth
1990 7.349.253.501
1991 7.351.895.512 0.04%
1992 6.034.914.231 -21.82%
1993 6.567.658.718 8.11%
1994 7.004.049.215 6.23%
1995 7.568.452.932 7.46%
1996 9.184.162.756 17.59%
1997 8.586.259.340 -6.96%
1998 9.145.987.218 6.12%
1999 18.435.929.209 50.39%
2000 18.115.963.675 -1.77%
2001 23.570.530.781 23.14%
2002 13.327.576.709 -76.86%
2003 14.380.000.000 7.32%
2004 16.233.000.000 11.42%
2005 18.594.000.000 12.7%
2006 20.916.000.000 11.1%
2007 23.555.000.000 11.2%
2008 25.003.000.000 5.79%
2009 27.029.000.000 7.5%
2010 26.880.000.000 -0.55%
2011 27.565.000.000 2.49%
2012 22.580.000.000 -22.08%
2013 20.450.000.000 -10.42%
2014 20.253.000.000 -0.97%
2015 20.062.000.000 -0.95%
2016 18.876.000.000 -6.28%
2017 18.147.000.000 -4.02%
2018 17.154.000.000 -5.79%
2019 19.463.000.000 11.86%
2020 21.318.000.000 8.7%
2021 24.980.000.000 14.66%
2022 31.960.000.000 21.84%
2023 37.588.000.000 14.97%
2023 34.693.179.753 -8.34%
2024 39.251.616.516 11.61%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AstraZeneca PLC Net Profit
Year Net Profit Growth
1990 428.224.219
1991 645.559.672 33.67%
1992 121.335.294 -432.05%
1993 637.536.240 80.97%
1994 692.587.902 7.95%
1995 519.191.544 -33.4%
1996 1.101.140.528 52.85%
1997 1.206.771.143 8.75%
1998 1.185.160.594 -1.82%
1999 1.142.437.233 -3.74%
2000 2.540.626.120 55.03%
2001 4.156.211.499 38.87%
2002 2.837.400.338 -46.48%
2003 3.036.000.000 6.54%
2004 3.664.000.000 17.14%
2005 4.706.000.000 22.14%
2006 6.043.000.000 22.12%
2007 5.595.000.000 -8.01%
2008 6.101.000.000 8.29%
2009 7.521.000.000 18.88%
2010 8.053.000.000 6.61%
2011 9.983.000.000 19.33%
2012 6.297.000.000 -58.54%
2013 2.556.000.000 -146.36%
2014 1.233.000.000 -107.3%
2015 2.825.000.000 56.35%
2016 3.499.000.000 19.26%
2017 3.001.000.000 -16.59%
2018 2.155.000.000 -39.26%
2019 1.335.000.000 -61.42%
2020 3.196.000.000 58.23%
2021 112.000.000 -2753.57%
2022 3.288.000.000 96.59%
2023 5.496.000.000 40.17%
2023 5.955.000.000 7.71%
2024 7.708.000.000 22.74%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AstraZeneca PLC Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1990 1
1991 1 0%
1992 0 0%
1993 1 0%
1994 1 0%
1995 1 0%
1996 1 100%
1997 1 0%
1998 1 0%
1999 1 0%
2000 1 100%
2001 2 0%
2002 2 0%
2003 178 99.44%
2004 218 18.35%
2005 3 -10800%
2006 4 33.33%
2007 4 0%
2008 4 25%
2009 5 20%
2010 6 0%
2011 7 28.57%
2012 5 -75%
2013 2 -100%
2014 1 0%
2015 2 100%
2016 3 0%
2017 2 0%
2018 2 -100%
2019 1 0%
2020 3 50%
2021 0 0%
2022 2 100%
2023 4 33.33%
2023 4 0%
2024 5 40%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AstraZeneca PLC Free Cashflow
Year Free Cashflow Growth
1990 266.193.433
1991 119.755.997 -122.28%
1992 -200.203.237 159.82%
1993 242.589.195 182.53%
1994 132.889.326 -82.55%
1995 154.521.292 14%
1996 148.987.909 -3.71%
1997 -8.265.556 1902.52%
1998 34.857.664 123.71%
1999 -1.843.094.022 101.89%
2000 875.253.912 310.58%
2001 443.826.976 -97.21%
2002 3.493.000.000 87.29%
2003 2.134.000.000 -63.68%
2004 4.541.000.000 53.01%
2005 5.764.000.000 21.22%
2006 6.354.000.000 9.29%
2007 5.831.000.000 -8.97%
2008 4.703.000.000 -23.98%
2009 8.782.000.000 46.45%
2010 8.260.000.000 -6.32%
2011 6.524.000.000 -26.61%
2012 2.329.000.000 -180.12%
2013 5.342.000.000 56.4%
2014 4.306.000.000 -24.06%
2015 536.000.000 -703.36%
2016 1.831.000.000 70.73%
2017 1.958.000.000 6.49%
2018 1.247.000.000 -57.02%
2019 509.000.000 -144.99%
2020 2.193.000.000 76.79%
2021 3.763.000.000 41.72%
2022 7.237.000.000 48%
2023 7.019.129.617 -3.1%
2023 2.235.000.000 -214.06%
2024 2.531.459.298 11.71%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AstraZeneca PLC Operating Cashflow
Year Operating Cashflow Growth
1990 806.296.053
1991 505.220.613 -59.59%
1992 206.270.001 -144.93%
1993 705.579.551 70.77%
1994 625.361.537 -12.83%
1995 585.635.700 -6.78%
1996 787.752.166 25.66%
1997 747.206.242 -5.43%
1998 879.741.057 15.07%
1999 908.552.801 3.17%
2000 2.336.001.911 61.11%
2001 2.706.514.973 13.69%
2002 4.833.000.000 44%
2003 3.416.000.000 -41.48%
2004 4.873.000.000 29.9%
2005 6.743.000.000 27.73%
2006 7.693.000.000 12.35%
2007 7.510.000.000 -2.44%
2008 8.742.000.000 14.09%
2009 11.739.000.000 25.53%
2010 10.680.000.000 -9.92%
2011 7.821.000.000 -36.56%
2012 6.948.000.000 -12.56%
2013 7.400.000.000 6.11%
2014 7.058.000.000 -4.85%
2015 3.324.000.000 -112.33%
2016 4.145.000.000 19.81%
2017 3.578.000.000 -15.85%
2018 2.618.000.000 -36.67%
2019 2.969.000.000 11.82%
2020 4.799.000.000 38.13%
2021 5.963.000.000 19.52%
2022 9.808.000.000 39.2%
2023 10.888.150.873 9.92%
2023 3.114.000.000 -249.65%
2024 3.203.202.788 2.78%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AstraZeneca PLC Capital Expenditure
Year Capital Expenditure Growth
1990 540.102.619
1991 385.464.616 -40.12%
1992 406.473.238 5.17%
1993 462.990.356 12.21%
1994 492.472.210 5.99%
1995 431.114.408 -14.23%
1996 638.764.257 32.51%
1997 755.471.798 15.45%
1998 844.883.393 10.58%
1999 2.751.646.823 69.3%
2000 1.460.747.999 -88.37%
2001 2.262.687.997 35.44%
2002 1.340.000.000 -68.86%
2003 1.282.000.000 -4.52%
2004 332.000.000 -286.14%
2005 979.000.000 66.09%
2006 1.339.000.000 26.89%
2007 1.679.000.000 20.25%
2008 4.039.000.000 58.43%
2009 2.957.000.000 -36.59%
2010 2.420.000.000 -22.19%
2011 1.297.000.000 -86.58%
2012 4.619.000.000 71.92%
2013 2.058.000.000 -124.44%
2014 2.752.000.000 25.22%
2015 2.788.000.000 1.29%
2016 2.314.000.000 -20.48%
2017 1.620.000.000 -42.84%
2018 1.371.000.000 -18.16%
2019 2.460.000.000 44.27%
2020 2.606.000.000 5.6%
2021 2.200.000.000 -18.45%
2022 2.571.000.000 14.43%
2023 3.869.021.256 33.55%
2023 879.000.000 -340.16%
2024 671.743.490 -30.85%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AstraZeneca PLC Equity
Year Equity Growth
1990 682.844.025
1991 916.881.852 25.53%
1992 169.869.412 -439.76%
1993 2.323.826.991 92.69%
1994 2.725.012.897 14.72%
1995 3.036.343.407 10.25%
1996 3.661.335.067 17.07%
1997 3.623.619.651 -1.04%
1998 4.226.076.852 14.26%
1999 10.336.919.243 59.12%
2000 9.548.631.855 -8.26%
2001 13.762.784.184 30.62%
2002 11.231.542.240 -22.54%
2003 13.257.000.000 15.28%
2004 14.497.000.000 8.55%
2005 13.691.000.000 -5.89%
2006 15.416.000.000 11.19%
2007 14.915.000.000 -3.36%
2008 16.060.000.000 7.13%
2009 20.821.000.000 22.87%
2010 23.410.000.000 11.06%
2011 23.472.000.000 0.26%
2012 23.952.000.000 2%
2013 23.253.000.000 -3.01%
2014 19.646.000.000 -18.36%
2015 18.509.000.000 -6.14%
2016 16.669.000.000 -11.04%
2017 16.642.000.000 -0.16%
2018 14.044.000.000 -18.5%
2019 14.596.000.000 3.78%
2020 15.638.000.000 6.66%
2021 39.287.000.000 60.2%
2022 37.058.000.000 -6.01%
2023 37.221.000.000 0.44%
2023 39.110.698.148 4.83%
2024 39.604.265.010 1.25%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AstraZeneca PLC Assets
Year Assets Growth
1990 6.101.230.662
1991 6.362.037.348 4.1%
1992 6.188.100.040 -2.81%
1993 7.424.116.916 16.65%
1994 7.318.293.388 -1.45%
1995 7.869.769.454 7.01%
1996 8.562.523.546 8.09%
1997 8.282.086.887 -3.39%
1998 8.979.998.340 7.77%
1999 19.806.258.897 54.66%
2000 18.446.050.902 -7.37%
2001 26.445.036.339 30.25%
2002 21.586.650.559 -22.51%
2003 23.573.000.000 8.43%
2004 25.652.000.000 8.1%
2005 24.840.000.000 -3.27%
2006 29.932.000.000 17.01%
2007 47.957.000.000 37.59%
2008 46.950.000.000 -2.14%
2009 54.920.000.000 14.51%
2010 56.127.000.000 2.15%
2011 52.830.000.000 -6.24%
2012 53.534.000.000 1.32%
2013 55.899.000.000 4.23%
2014 58.595.000.000 4.6%
2015 60.124.000.000 2.54%
2016 62.526.000.000 3.84%
2017 63.354.000.000 1.31%
2018 60.651.000.000 -4.46%
2019 61.377.000.000 1.18%
2020 66.729.000.000 8.02%
2021 105.363.000.000 36.67%
2022 96.483.000.000 -9.2%
2023 96.086.000.000 -0.41%
2023 100.976.221.368 4.84%
2024 104.356.508.188 3.24%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AstraZeneca PLC Liabilities
Year Liabilities Growth
1990 5.418.386.636
1991 5.445.155.495 0.49%
1992 6.018.230.628 9.52%
1993 5.100.289.923 -18%
1994 4.593.280.490 -11.04%
1995 4.833.426.046 4.97%
1996 4.901.188.478 1.38%
1997 4.658.467.235 -5.21%
1998 4.753.921.487 2.01%
1999 9.469.339.653 49.8%
2000 8.897.419.046 -6.43%
2001 12.682.252.154 29.84%
2002 10.355.108.319 -22.47%
2003 10.316.000.000 -0.38%
2004 11.155.000.000 7.52%
2005 11.149.000.000 -0.05%
2006 14.516.000.000 23.2%
2007 33.042.000.000 56.07%
2008 30.890.000.000 -6.97%
2009 34.099.000.000 9.41%
2010 32.717.000.000 -4.22%
2011 29.358.000.000 -11.44%
2012 29.582.000.000 0.76%
2013 32.646.000.000 9.39%
2014 38.949.000.000 16.18%
2015 41.615.000.000 6.41%
2016 45.857.000.000 9.25%
2017 46.712.000.000 1.83%
2018 46.607.000.000 -0.23%
2019 46.781.000.000 0.37%
2020 51.091.000.000 8.44%
2021 66.076.000.000 22.68%
2022 59.425.000.000 -11.19%
2023 58.865.000.000 -0.95%
2023 61.865.523.219 4.85%
2024 64.752.243.177 4.46%

AstraZeneca PLC Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
31.88
Net Income per Share
4.15
Price to Earning Ratio
37.48x
Price To Sales Ratio
4.89x
POCF Ratio
21.19
PFCF Ratio
33.17
Price to Book Ratio
6.11
EV to Sales
5.42
EV Over EBITDA
18.34
EV to Operating CashFlow
23.53
EV to FreeCashFlow
36.83
Earnings Yield
0.03
FreeCashFlow Yield
0.03
Market Cap
241,41 Bil.
Enterprise Value
268,03 Bil.
Graham Number
48.82
Graham NetNet
-29.27

Income Statement Metrics

Net Income per Share
4.15
Income Quality
1.69
ROE
0.17
Return On Assets
0.06
Return On Capital Employed
0.12
Net Income per EBT
0.82
EBT Per Ebit
0.86
Ebit per Revenue
0.18
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.81
Operating Profit Margin
0.18
Pretax Profit Margin
0.15
Net Profit Margin
0.13

Dividends

Dividend Yield
0.02
Dividend Yield %
1.9
Payout Ratio
0.69
Dividend Per Share
2.96

Operating Metrics

Operating Cashflow per Share
7.35
Free CashFlow per Share
4.7
Capex to Operating CashFlow
0.36
Capex to Revenue
0.08
Capex to Depreciation
0.79
Return on Invested Capital
0.11
Return on Tangible Assets
0.15
Days Sales Outstanding
93.24
Days Payables Outstanding
635.47
Days of Inventory on Hand
175.99
Receivables Turnover
3.91
Payables Turnover
0.57
Inventory Turnover
2.07
Capex per Share
2.65

Balance Sheet

Cash per Share
4,57
Book Value per Share
25,55
Tangible Book Value per Share
-13.47
Shareholders Equity per Share
25.5
Interest Debt per Share
22.13
Debt to Equity
0.82
Debt to Assets
0.31
Net Debt to EBITDA
1.82
Current Ratio
0.89
Tangible Asset Value
-20,88 Bil.
Net Current Asset Value
-39,36 Bil.
Invested Capital
68147211929
Working Capital
-3,17 Bil.
Intangibles to Total Assets
0.58
Average Receivables
12,42 Bil.
Average Payables
20,08 Bil.
Average Inventory
5500441514.5
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AstraZeneca PLC Dividends
Year Dividends Growth
2014 3
2015 3 0%
2016 3 -50%
2017 3 0%
2018 3 0%
2019 3 0%
2020 3 0%
2021 3 0%
2022 3 0%
2023 3 0%
2024 3 0%

AstraZeneca PLC Profile

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CEO
Mr. Pascal Soriot D.V.M., M.B
Employee
89.900
Address
1 Francis Crick Avenue
Cambridge, CB2 0AA

AstraZeneca PLC Executives & BODs

AstraZeneca PLC Executives & BODs
# Name Age
1 Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
70
2 Mr. Jeffrey Pott J.D.
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
70
3 Dr. Susan Mary Galbraith M.D., Ph.D.
Executive Vice President of Oncology Research & Development
70
4 Ms. Iskra Reic
Executive Vice President of International
70
5 Mr. David Fredrickson
Executive Vice-President of Oncology Business Unit
70
6 Ms. Pam P. Cheng
EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
70
7 Mr. Andrew P. Barnett
Head of Investor Relations
70
8 Mr. Pascal Soriot D.V.M., M.B.A.
Chief Executive Officer & Executive Director
70
9 Gonzalo Vina
Head of Global Media Relations
70
10 Dr. Aradhana Sarin M.D.
Chief Financial Officer & Executive Director
70

AstraZeneca PLC Competitors